Emer Leahy
Independent DirectorDr. Emer Leahy, Ph.D. M.B.A, was Chairman of the Board of BioNJ Inc. until February 05, 2026. Dr. Leahy served as Director of NeuroNascent, Inc. since April 2023 until July 2025. She serves as Director at Pasithea Therapeutics Corp. since June 2021. She has been the Chief Executive Officer and President of PsychoGenics Inc. since 2000 and is its Director. Dr. Leahy serves as the Chief Executive Officer of Psylin Neurosciences, Inc. She has CNS drug discovery experience, as well as experience in business development for pharmaceutical and biotechnology companies. She was the Chair of the Board of Trustees of BioNJ until February 05, 2026. Dr. Leahy is also the chief executive officer of PGI Drug Discovery LLC since 2011. She holds an Adjunct Associate Professor of Neuroscience position at Mount Sinai School of Medicine. She served as Vice President of Business Development of PsychoGenics Inc. Previously, Dr. Leahy served as Senior Vice President of Business Development at American Biogenetic Sciences (ABS), where she spearheaded a number of contract negotiations and licensing agreements focusing on Alzheimer's Disease, psychiatry, epilepsy and other neurodegenerative disorders. Prior to her engagement at ABS, Dr. Leahy served as Vice President of Business Development at AMBI Inc. a pharmaceutical firm developing products for cardiovascular conditions and infectious diseases. Over the past ten years, she served a variety of positions in pharmaceutical and biotechnology companies, where she gained considerable business development experience in technology assessment, licensing, mergers and acquisitions and strategic planning. Dr. Leahy has been an Independent Director of Intensity Therapeutics, Inc. since June 28, 2016. Dr. Leahy serves as a Director of Psylin Neurosciences, Inc. Dr. Leahy served on the Emerging Companies Section Governing Board for the Board of Directors of the Biotechnology Industry Organization (BIO), the Business Review Board for the Alzheimer Drug Discovery Foundation and the Scientific Advisory Board of the International Rett Syndrome Foundation. She also served on the Board of Directors of Bright Minds Biosciences Inc. until April 2022. She has been Director at Pasithea Therapeutics and on the Board of Trustees of BIONJ since February 2024 until February 05, 2026. Dr. Leahy received PhD in Neuropharmacology at University College Dublin, Ireland and MBA from Columbia University, New York.
Positions
- Company NamePasithea Therapeutics Corp.Stock CodeKTTAPositionIndependent Director
- Company NameIntensity Therapeutics, Inc.Stock CodeINTSPositionIndependent DirectorColleagues
- LHLewis H. BenderFounder, President, CEO & Chairman of the Board
- JTJoseph TalamoChief Financial Officer
- JWJohn WesolowskiPrincipal Accounting Officer & Controller
- JMJames M. AhlersExecutive Vice President of Corporate Finance
- ELEmer LeahyIndependent Director
- MAMark A. GoldbergIndependent Director
- DJDaniel J. DonovanIndependent Director
- RLRiccardo LencioniMember of Scientific Advisory Board
- Company NameBright Minds Biosciences Inc.Stock CodeDRUGPositionConsultantColleagues
- IMIan McDonaldCo-Founder, CEO, President & Director
- RERyan E. S. K. CheungCFO & Corporate Secretary
- JTJan Torleif PedersenChief Science Officer & Director
- AVAlex VasilkevichCOO & Senior Scientific Officer
- ELEmer LeahyConsultant
- NCNils Christian BottlerIndependent Director
- JFJeremy FryzukIndependent Director
- HYHerbert Y. MeltzerMember of Scientific Advisory Board
